<DOC>
	<DOCNO>NCT02929030</DOCNO>
	<brief_summary>The study aim evaluate safety efficacy polymer-free sirolimus-eluting coronary stent system ( NANO plus ) patient coronary artery disease . The primary endpoint target lesion failure , composite endpoint cardiac death , target vessel related myocardial infarction clinically-driven target lesion revascularization 1 year follow-up .</brief_summary>
	<brief_title>Clinical Performance Nano Plus Sirolimus-Eluting Stents Patients With Coronary Artery Disease</brief_title>
	<detailed_description>This prospective , multicenter , single arm clinical registry investigate safety efficacy polymer-free sirolimus-eluting coronary stent system ( NANO plus ) patient coronary artery disease . In total , plan recruit 2500 patient real world setting . The patient follow clinically 1- , 6- month 1- , 2- , 3- , 4- , 5-year . All clinical data collect managed statistical center , clinical endpoint adjudication committee .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1885 year old , male nonpregnancy female ; Patients coronary artery disease match indication stent implantation ; Patients understand nature study , agree participate accept clinical followup ; Patients tolerate material medication study ; Pregnancy lactation woman Patients participate another investigational drug device trial complete primary endpoint ; Patients , opinion investigator , unable comply requirement study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>